Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBP 8088

Next Previous
X
Search
Drug Profile

CBP 8088

Alternative Names: CBP-8088

Latest Information Update: 06 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Coherent Biopharma (Suzhou)
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action Proteolysis
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer; Triple negative breast cancer

Most Recent Events

  • 06 Aug 2024 Preclinical trials in Prostate cancer in China (unspecified route) prior to August 2024 (Coherent Biopharma (Suzhou) pipeline, August 2024)
  • 06 Aug 2024 Preclinical trials in Triple-negative-breast-cancer in China (unspecified route) prior to August 2024 (Coherent Biopharma (Suzhou) pipeline, August 2024)
  • 07 Feb 2023 Coherent Biopharma (Suzhou) has patent protection for multi-ligand drug conjugates and uses thereof in the US, Europe, Canada, South Korea, China, Japan, and Russia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top